2024
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Kerekes D, Frey A, Prsic E, Tran T, Clune J, Sznol M, Kluger H, Forman H, Becher R, Olino K, Khan S. Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. JAMA Oncology 2024, 10: 342-351. PMID: 38175659, PMCID: PMC10767643, DOI: 10.1001/jamaoncol.2023.6025.Peer-Reviewed Original ResearchNon-small cell lung cancerEnd of lifeMonth of deathImmunotherapy initiationCohort studyMAIN OUTCOMEStage IV non-small cell lung cancerCharlson-Deyo comorbidity indexHigh metastatic burdenInitiation of immunotherapyNational prescribing patternsRisk-adjusted patientsImmune checkpoint inhibitorsRetrospective cohort studyStage IV melanomaPercentage of patientsHigh-volume centersLocation of metastasesLow-volume centersOdds of deathCell lung cancerNational Clinical DatabaseLow-volume facilitiesDrug Administration approvalCheckpoint inhibitorsMeaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary
Papp K, Gordon K, Strober B, Zhuo J, Becker B, Zhong Y, Beaumont J, Pham T, Kisa R, Napoli A, Banerjee S, Armstrong A. Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary. JAMA Dermatology 2024, 160: 204-209. PMID: 38117487, PMCID: PMC10733845, DOI: 10.1001/jamadermatol.2023.5058.Peer-Reviewed Original ResearchSevere plaque psoriasisPatient Global ImpressionClinical trialsPsoriasis symptomsScore changeSigns DiaryPlaque psoriasisGlobal ImpressionWeek 16MAIN OUTCOMEPatient-reported end pointsPlacebo-controlled phase 3 clinical trialPhase 3 clinical trialsPatient-reported assessmentsPhase 3 programMeaningful change thresholdCategory improvementDisease burdenMeaningful score changesSelective TYK2 inhibitorsPatient changeBaseline scoresPsoriasisPatientsEnd pointMeasuring Equity in Readmission as a Distinct Assessment of Hospital Performance
Nash K, Weerahandi H, Yu H, Venkatesh A, Holaday L, Herrin J, Lin Z, Horwitz L, Ross J, Bernheim S. Measuring Equity in Readmission as a Distinct Assessment of Hospital Performance. JAMA 2024, 331: 111-123. PMID: 38193960, PMCID: PMC10777266, DOI: 10.1001/jama.2023.24874.Peer-Reviewed Original ResearchConceptsBlack patientsPatient populationHospital characteristicsHospital-wide readmission measureDual-eligible patientsHospital patient populationCross-sectional studyMeasures of hospitalHealth care qualityPatient demographicsReadmission ratesClinical outcomesPatient raceEligible hospitalsReadmissionMAIN OUTCOMEReadmission measuresMedicare dataUS hospitalsHospitalCare qualityPatientsMedicaid ServicesOutcomesLower percentageUtilization of Cryopreserved Oocytes in Patients With Poor Ovarian Response After Planned Oocyte Cryopreservation
Fouks Y, Sakkas D, Bortoletto P, Penzias A, Seidler E, Vaughan D. Utilization of Cryopreserved Oocytes in Patients With Poor Ovarian Response After Planned Oocyte Cryopreservation. JAMA Network Open 2024, 7: e2349722. PMID: 38165675, PMCID: PMC10762568, DOI: 10.1001/jamanetworkopen.2023.49722.Peer-Reviewed Original ResearchConceptsPoor ovarian responseOvarian responseOocyte cryopreservationCryopreserved oocytesCohort studyNormal ovarian responseNormal responder groupOvarian stimulation cyclesHistory of endometriosisBody mass indexNumber of patientsNumber of oocytesTiming of patientsNormal respondersPOR groupEligible patientsUS fertility clinicsMass indexResponder groupStimulation cyclesHigher oddsMAIN OUTCOMEAge 35Patient's desirePatients
2023
Association between serum 25-hydroxyvitamin D and antimüllerian hormone levels in a cohort of African-American women
Subramanian A, Harmon Q, Bernardi L, Carnethon M, Marsh E, Baird D, Jukic A. Association between serum 25-hydroxyvitamin D and antimüllerian hormone levels in a cohort of African-American women. Fertility And Sterility 2023, 121: 642-650. PMID: 38145700, PMCID: PMC10978232, DOI: 10.1016/j.fertnstert.2023.12.023.Peer-Reviewed Original ResearchHigher AMH levelsLower AMH levelsAMH levelsAfrican American womenHigher oddsMAIN OUTCOMELower oddsAntimüllerian hormone levelsSerum AMH levelsPolycystic ovary syndromeHormonal contraceptive useBody mass indexTime of enrollmentCross-sectional studyExclusion of participantsClinical trial designAntimüllerian hormoneOvarian reserveOvary syndromeProspective cohortMass indexPrior diagnosisD levelsHormone levelsContraceptive useHospital Admissions for Abusive Head Trauma Before and During the COVID-19 Pandemic
Maassel N, Graetz E, Schneider E, Asnes A, Solomon D, Leventhal J. Hospital Admissions for Abusive Head Trauma Before and During the COVID-19 Pandemic. JAMA Pediatrics 2023, 177: 1342-1347. PMID: 37870839, PMCID: PMC10594171, DOI: 10.1001/jamapediatrics.2023.4519.Peer-Reviewed Original ResearchConceptsAbusive head traumaCross-sectional studyMonthly hospitalizationsHead traumaClinical characteristicsSignificant decreaseCOVID-19 pandemicPediatric Health Information SystemTertiary care children's hospitalMean monthly incidenceClinical Modification codesHospitalization of childrenInterrupted time series analysisCOVID-19Subgroup of childrenHospital admissionChildren's HospitalTenth RevisionHospitalizationMAIN OUTCOMEInternational ClassificationSevere formCOVID-19 periodHealth information systemsPreventive effortsChanges in Older Adult Trauma Quality When Evaluated Using Longer-Term Outcomes vs In-Hospital Mortality
Zogg C, Cooper Z, Peduzzi P, Falvey J, Castillo-Angeles M, Kodadek L, Staudenmayer K, Davis K, Tinetti M, Lichtman J. Changes in Older Adult Trauma Quality When Evaluated Using Longer-Term Outcomes vs In-Hospital Mortality. JAMA Surgery 2023, 158: e234856. PMID: 37792354, PMCID: PMC10551815, DOI: 10.1001/jamasurg.2023.4856.Peer-Reviewed Original ResearchConceptsHospital-level factorsTraumatic brain injurySevere traumatic brain injuryHospital mortalityTrauma QualityOlder adultsHip fractureComposite scoreHigher risk-adjusted oddsLevel 1 trauma centerIn-Hospital MortalityRisk-adjusted oddsLong-term outcomesMultivariable logistic regressionNontrauma centersTrauma patientsTerm outcomesTrauma centerPrimary diagnosisBrain injuryTrauma systemMAIN OUTCOMEMedicare feeService claimsForms of traumaPatient Preferences for Postmastectomy Breast Reconstruction
Shammas R, Hung A, Mullikin A, Sergesketter A, Lee C, Reed S, Fish L, Greenup R, Hollenbeck S. Patient Preferences for Postmastectomy Breast Reconstruction. JAMA Surgery 2023, 158: 1285-1292. PMID: 37755818, PMCID: PMC10535024, DOI: 10.1001/jamasurg.2023.4432.Peer-Reviewed Original ResearchConceptsRisk of complicationsBreast reconstructionAbdominal morbidityFlap reconstructionBreast cancerGenetic predispositionPatient-physician discussionsImplant-based reconstructionPostmastectomy breast reconstructionCross-sectional studyChance of complicationsPatient-centered careAdditional operationsHigher educational levelMajor complicationsPreoperative counselingPatient preferencesFlap appearanceTreatment preferencesImplant reconstructionMAIN OUTCOMENew diagnosisPatient valuesComplicationsMean increaseEtiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease
Shirzadi Z, Schultz S, Yau W, Joseph-Mathurin N, Fitzpatrick C, Levin R, Kantarci K, Preboske G, Jack C, Farlow M, Hassenstab J, Jucker M, Morris J, Xiong C, Karch C, Levey A, Gordon B, Schofield P, Salloway S, Perrin R, McDade E, Levin J, Cruchaga C, Allegri R, Fox N, Goate A, Day G, Koeppe R, Chui H, Berman S, Mori H, Sanchez-Valle R, Lee J, Rosa-Neto P, Ruthirakuhan M, Wu C, Swardfager W, Benzinger T, Sohrabi H, Martins R, Bateman R, Johnson K, Sperling R, Greenberg S, Schultz A, Chhatwal J, Weiner M, Aisen P, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Saykin A, Morris J, Perrin R, Shaw L, Khachaturian Z, Carrillo M, Potter W, Barnes L, Bernard M, González H, Ho C, Hsiao J, Jackson J, Masliah E, Masterman D, Okonkwo O, Ryan L, Silverberg N, Fleisher A, Sacrey D, Fockler J, Conti C, Veitch D, Neuhaus J, Jin C, Nosheny R, Ashford M, Flenniken D, Kormos A, Montine T, Rafii M, Raman R, Jimenez G, Donohue M, Gessert D, Salazar J, Zimmerman C, Cabrera Y, Walter S, Miller G, Coker G, Clanton T, Hergesheimer L, Smith S, Adegoke O, Mahboubi P, Moore S, Pizzola J, Shaffer E, Sloan B, Harvey D, Forghanian-Arani A, Borowski B, Ward C, Schwarz C, Jones D, Gunter J, Kantarci K, Senjem M, Vemuri P, Reid R, Fox N, Malone I, Thompson P, Thomopoulos S, Nir T, Jahanshad N, DeCarli C, Knaack A, Fletcher E, Tosun-Turgut D, Chen S, Choe M, Crawford K, Yushkevich P, Das S, Koeppe R, Reiman E, Chen K, Mathis C, Landau S, Cairns N, Householder E, Franklin E, Bernhardt H, Taylor-Reinwald L, Korecka M, Figurski M, Neu S, Nho K, Risacher S, Apostolova L, Shen L, Foroud T, Nudelman K, Faber K, Wilmes K, Thal L, Silbert L, Lind B, Crissey R, Kaye J, Carter R, Dolen S, Quinn J, Schneider L, Pawluczyk S, Becerra M, Teodoro L, Dagerman K, Spann B, Brewer J, Vanderswag H, Ziolkowski J, Heidebrink J, Zbizek-Nulph L, Lord J, Mason S, Albers C, Knopman D, Johnson K, Villaneuva-Meyer J, Pavlik V, Pacini N, Lamb A, Kass J, Doody R, Shibley V, Chowdhury M, Rountree S, Dang M, Stern Y, Honig L, Mintz A, Ances B, Winkfield D, Carroll M, Stobbs-Cucchi G, Oliver A, Creech M, Mintun M, Schneider S, Geldmacher D, Love M, Griffith R, Clark D, Brockington J, Marson D, Grossman H, Goldstein M, Greenberg J, Mitsis E, Shah R, Lamar M, Samuels P, Duara R, Greig-Custo M, Rodriguez R, Albert M, Onyike C, Farrington L, Rudow S, Brichko R, Kielb S, Smith A, Raj B, Fargher K, Sadowski M, Wisniewski T, Shulman M, Faustin A, Rao J, Castro K, Ulysse A, Chen S, Sheikh M, Singleton-Garvin J, Doraiswamy P, Petrella J, James O, Wong T, Borges-Neto S, Karlawish J, Wolk D, Vaishnavi S, Clark C, Arnold S, Smith C, Jicha G, El Khouli R, Raslau F, Lopez O, Oakley M, Simpson D, Porsteinsson A, Martin K, Kowalski N, Keltz M, Goldstein B, Makino K, Ismail M, Brand C, Thai G, Pierce A, Yanez B, Sosa E, Witbracht M, Kelley B, Nguyen T, Womack K, Mathews D, Quiceno M, Levey A, Lah J, Hajjar I, Cellar J, Burns J, Swerdlow R, Brooks W, Silverman D, Kremen S, Tingus K, Lu P, Bartzokis G, Woo E, Teng E, Graff-Radford N, Parfitt F, Poki-Walker K, Farlow M, Hake A, Matthews B, Brosch J, Herring S, van Dyck C, Mecca A, Good S, MacAvoy M, Carson R, Varma P, Chertkow H, Vaitekunis S, Hosein C, Black S, Stefanovic B, Heyn C, Hsiung G, Kim E, Mudge B, Sossi V, Feldman H, Assaly M, Finger E, Pasternak S, Rachinsky I, Kertesz A, Drost D, Rogers J, Grant I, Muse B, Rogalski E, Robson J, Mesulam M, Kerwin D, Wu C, Johnson N, Lipowski K, Weintraub S, Bonakdarpour B, Pomara N, Hernando R, Sarrael A, Rosen H, Miller B, Perry D, Turner R, Johnson K, Reynolds B, MCCann K, Poe J, Sperling R, Johnson K, Marshall G, Yesavage J, Taylor J, Chao S, Coleman J, White J, Lane B, Rosen A, Tinklenberg J, Belden C, Atri A, Clark K, Zamrini E, Sabbagh M, Killiany R, Stern R, Mez J, Kowall N, Budson A, Obisesan T, Ntekim O, Wolday S, Khan J, Nwulia E, Nadarajah S, Lerner A, Ogrocki P, Tatsuoka C, Fatica P, Maillard P, Olichney J, Carmichael O, Bates V, Capote H, Rainka M, Borrie M, Lee T, Bartha R, Johnson S, Asthana S, Carlsson C, Perrin A, Burke A, Scharre D, Kataki M, Tarawneh R, Hart D, Zimmerman E, Celmins D, Miller D, Boles Ponto L, Smith K, Koleva H, Shim H, Nam K, Schtulz S, Williamson J, Craft S, Cleveland J, Yang M, Sink K, Ott B, Drake J, Tremont G, Daiello L, Ritter A, Bernick C, Munic D, O'Connell A, Mintzer J, Wiliams A, Masdeu J, Shi J, Garcia A, Newhouse P, Potkin S, Salloway S, Malloy P, Correia S, Kittur S, Pearlson G, Blank K, Anderson K, Flashman L, Seltzer M, Hynes M, Santulli R, Relkin N, Chiang G, Lee A, Lin M, Ravdin L, Sood A, Blanchard K, Fleischman D, Arfanakis K, Varon D, Greig M, Goldstein B, Martin K, Reist C, Sadowsky C, Martinez W, Villena T, Rosen H, Marshall G, Peskind E, Petrie E, Li G, Noble J, Voglein J, Chrem Mendez P, Surace E, Ikonomovic S, Nadkarni N, Lopera F, Ramirez L, Aguillon D, Leon Y, Ramos C, Alzate D, Baena A, Londono N, Moreno S, Laske C, Kuder-Buletta E, Graber-Sultan S, Preische O, Hofmann A, Ikeuchi T, Kasuga K, Niimi Y, Ishii K, Senda M, Cash D, Roh J, Riddle M, Menard W, Bodge C, Surti M, Takada L, Farlow M, Sanchez-Gonzalez V, Orozco-Barajas M, Renton A, Esposito B, Karch C, Marsh J, Fernanadez V, Jerome G, Herries E, Llibre-Guerra J, Johnson E, Seyfried N, Brooks W, Bechara J, Franklin E, Chen A, Chen C, Flores S, Hantler N, Hornbeck R, Jarman S, Keefe S, Koudelis D, Massoumzadeh P, McCullough A, McKay N, Nicklaus J, Pulizos C, Wang Q, Mishall S, Sabaredzovic E, Deng E, Candela M, Smith H, Hobbs D, Scott J, Xiong C, Wang P, Xu X, Li Y, Gremminger E, Ma Y, Bui R, Lu R, Martins R, Sosa Ortiz A, Daniels A, Courtney L, Mori H, Supnet-Bell, PhD (CSB) C, Xu J, Ringman J, Barthelemy N, Smith J. Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease. JAMA Neurology 2023, 80: 1353-1363. PMID: 37843849, PMCID: PMC10580156, DOI: 10.1001/jamaneurol.2023.3618.Peer-Reviewed Original ResearchConceptsSystemic vascular riskAutosomal dominant Alzheimer's diseaseLate-onset Alzheimer's diseaseVascular riskWMH volumeGray matter volumeAlzheimer's diseaseCohort studyOlder adultsDisease Neuroimaging InitiativeMAIN OUTCOMEMatter volumeCommon magnetic resonance imaging findingCommunity-based medical centerSystemic vascular risk factorsMagnetic resonance imaging (MRI) findingsWhite matter hyperintensity volumeHarvard Aging Brain StudyVascular risk factorsResonance Imaging FindingsLongitudinal cohort studyGreater WMH volumeSporadic Alzheimer's diseasePathogenic variant carriersWhite matter hyperintensitiesBarriers to Care Among Sexual and Gender Minority Individuals With Chronic Inflammatory Skin Diseases in the US
Nock M, Kamal K, Zampella J, Roberson M, Cohen J, Barbieri J. Barriers to Care Among Sexual and Gender Minority Individuals With Chronic Inflammatory Skin Diseases in the US. JAMA Dermatology 2023, 159: 1323-1331. PMID: 37755822, PMCID: PMC10535014, DOI: 10.1001/jamadermatol.2023.3328.Peer-Reviewed Original ResearchConceptsChronic inflammatory skin diseaseInflammatory skin diseaseHealth care practitionersCross-sectional studySGM patientsPrevalence of barriersCare practitionersGender minority patientsSkin diseasesMinority patientsMAIN OUTCOMEHealth careMultivariable logistic regressionHealth care accessMental health careSpecialist careCare accessPatientsUs Research ProgramLogistic regressionCarePrevalenceDiseaseNational InstituteGender minority individualsRace and Ethnicity and Emergency Department Discharge Against Medical Advice
Tsai J, Janke A, Krumholz H, Khidir H, Venkatesh A. Race and Ethnicity and Emergency Department Discharge Against Medical Advice. JAMA Network Open 2023, 6: e2345437. PMID: 38015503, PMCID: PMC10685883, DOI: 10.1001/jamanetworkopen.2023.45437.Peer-Reviewed Original ResearchConceptsWhite patientsHispanic patientsEmergency departmentCross-sectional studyED visitsBlack patientsDAMA rateMedical adviceMAIN OUTCOMEEthnic disparitiesNationwide Emergency Department SampleNational cross-sectional studyHospital ED visitsEmergency department dischargeHospital-level variationEmergency Department SampleMetropolitan teaching hospitalHealth care resourcesMedian ageGreater morbidityHospital variationUnadjusted analysesTeaching hospitalAdditional adjustmentLower oddsPembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer
Takahashi M, Cortés J, Dent R, Pusztai L, McArthur H, Kümmel S, Denkert C, Park Y, Im S, Ahn J, Mukai H, Huang C, Chen S, Kim M, Jia L, Li X, Tryfonidis K, Karantza V, Iwata H, Schmid P. Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer. JAMA Network Open 2023, 6: e2342107. PMID: 37966841, PMCID: PMC10652156, DOI: 10.1001/jamanetworkopen.2023.42107.Peer-Reviewed Original ResearchConceptsEarly triple-negative breast cancerTriple-negative breast cancerEvent-free survivalPathologic complete responseChemotherapy groupNeoadjuvant chemotherapyBreast cancerNeoadjuvant pembrolizumabDefinitive surgeryComplete responseMAIN OUTCOMEEastern Cooperative Oncology Group performance statusCell death ligand 1 (PD-L1) statusDeath ligand 1 (PD-L1) statusTreatment-related adverse eventsNonmetastatic triple-negative breast cancerCycles of pembrolizumabPembrolizumab Plus ChemotherapyTumor PD-L1Unacceptable toxic effectsPD-L1 statusOverall survival analysisAdjuvant pembrolizumabEFS eventsEFS ratesFloods and Diarrhea Risk in Young Children in Low- and Middle-Income Countries
Wang P, Asare E, Pitzer V, Dubrow R, Chen K. Floods and Diarrhea Risk in Young Children in Low- and Middle-Income Countries. JAMA Pediatrics 2023, 177: 1206-1214. PMID: 37782513, PMCID: PMC10546297, DOI: 10.1001/jamapediatrics.2023.3964.Peer-Reviewed Original ResearchConceptsMiddle-income countriesDiarrhea riskOdds ratioMAIN OUTCOMEMixed-effects logistic regression modelRisk of diarrheaCross-sectional studyHigher odds ratioPrevalence of diarrheaLogistic regression modelsHealth survey programUnexposed childrenEffect modificationChild healthDiarrhea prevalenceSurvey clustersSignificant associationHygiene practicesFourth weekWeeksStrong associationRandom interceptYoung childrenChildrenDiarrheaBrain Networks and Adolescent Alcohol Use
Yip S, Lichenstein S, Liang Q, Chaarani B, Dager A, Pearlson G, Banaschewski T, Bokde A, Desrivières S, Flor H, Grigis A, Gowland P, Heinz A, Brühl R, Martinot J, Martinot M, Artiges E, Nees F, Orfanos D, Paus T, Poustka L, Hohmann S, Millenet S, Fröhner J, Smolka M, Vaidya N, Walter H, Whelan R, Schumann G, Garavan H. Brain Networks and Adolescent Alcohol Use. JAMA Psychiatry 2023, 80: 1131-1141. PMID: 37647053, PMCID: PMC10469292, DOI: 10.1001/jamapsychiatry.2023.2949.Peer-Reviewed Original ResearchConceptsAlcohol Use Disorders Identification TestAlcohol use riskAlcohol misuseUse riskAlcohol use disorderMale adolescentsDisorders Identification TestSingle-site studyIntervention effortsWhole-brain patternsMean ageAlcohol use dataLeading causeMagnetic resonance imaging dataMAIN OUTCOMEReward-related processesHigh riskSeparate cohortUse disordersAlcohol consumptionCurrent severityAdolescent neurodevelopmentAlcohol use behaviorsAlcohol useAUDIT scoresIncidence of Lung Adenocarcinoma by Age, Sex, and Smoking Status in Taiwan
Chien L, Jiang H, Tsai F, Chang H, Freedman N, Rothman N, Lan Q, Hsiung C, Chang I. Incidence of Lung Adenocarcinoma by Age, Sex, and Smoking Status in Taiwan. JAMA Network Open 2023, 6: e2340704. PMID: 37910104, PMCID: PMC10620613, DOI: 10.1001/jamanetworkopen.2023.40704.Peer-Reviewed Original ResearchConceptsNational Health Insurance Research DatabaseTaiwan Cancer RegistryNational Health Interview SurveyLung ADCSmoking statusIncidence rate ratiosHealth Interview SurveyTumor stageRisk factorsCohort studyIncidence rateMAIN OUTCOMEHigher ageLung cancer prevention strategiesMale incidence rate ratiosPopulation-based cohort studyTaiwan National Health Interview SurveyHealth Insurance Research DatabaseLung adenocarcinoma incidenceInterview SurveyCancer prevention strategiesEffect of smokingInvasive lung cancerCancer-free individualsHigh tobacco usePolygenic Risk Score, Environmental Tobacco Smoke, and Risk of Lung Adenocarcinoma in Never-Smoking Women in Taiwan
Blechter B, Chien L, Chen T, Chang I, Choudhury P, Hsiao C, Shu X, Wong J, Chen K, Chang G, Tsai Y, Su W, Huang M, Chen Y, Chen C, Hung H, Hu J, Shi J, Zheng W, Rositch A, Chen C, Chatterjee N, Yang P, Rothman N, Hsiung C, Lan Q. Polygenic Risk Score, Environmental Tobacco Smoke, and Risk of Lung Adenocarcinoma in Never-Smoking Women in Taiwan. JAMA Network Open 2023, 6: e2339254. PMID: 37955902, PMCID: PMC10644212, DOI: 10.1001/jamanetworkopen.2023.39254.Peer-Reviewed Original ResearchConceptsEnvironmental tobacco smokeAbsolute riskLung adenocarcinomaPolygenic risk scoresETS exposureTobacco smokeRisk scoreLung cancer risk factorsLung cancer screening programsGenetic susceptibilityLung cancer incidence ratesLifetime absolute riskCancer screening programsCancer risk factorsCase-control studyCancer incidence ratesRelative risk estimatesOverall genetic susceptibilitySuper-additive interactionRecent genome-wide association studiesLung cancerIncidence rateRisk factorsScreening programMAIN OUTCOMECumulative live birth rates with autologous oocytes plateau with fewer number of cycles for each year of age > 42
Seifer D, Wang S, Frankfurter D. Cumulative live birth rates with autologous oocytes plateau with fewer number of cycles for each year of age > 42. Reproductive Biology And Endocrinology 2023, 21: 94. PMID: 37872609, PMCID: PMC10591412, DOI: 10.1186/s12958-023-01144-z.Peer-Reviewed Original ResearchConceptsCumulative live birth rateLive birth rateART cyclesBirth rateDesignRetrospective cohort studyPrior ART cyclesUse of ICSIEtiology of infertilityNumber of oocytesAge categoriesSART CORS databaseYears of ageTreatment cycle numberRace/ethnicityAutologous cyclesResultsBetween 2014Ovarian reserveCohort studyBlastocyst transferWomen 46Women 42Age 45Live birthsMAIN OUTCOMEPhysician expectationsAlterations in Cancer Treatment During the First Year of the COVID-19 Pandemic in the US
Janczewski L, Cotler J, Merkow R, Palis B, Nelson H, Mullett T, Boffa D. Alterations in Cancer Treatment During the First Year of the COVID-19 Pandemic in the US. JAMA Network Open 2023, 6: e2340148. PMID: 37902756, PMCID: PMC10616721, DOI: 10.1001/jamanetworkopen.2023.40148.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseCancer treatmentAcademic hospitalCommunity hospitalMAIN OUTCOMECOVID-19 pandemicProportion of patientsRetrospective cohort studyAvailability of treatmentFirst yearUnderwent surgeryCohort studyMedian ageCancer surgeryMedian timeTreatment of cancerCancer careTreatment modalitiesCancer screeningCancer DatabaseMedian travel distancePatientsHospitalSurgeryCancerPerinatal Trajectories of Maternal Depressive Symptoms in Prospective, Community-Based Cohorts Across 3 Continents
Kee M, Cremaschi A, De Iorio M, Chen H, Montreuil T, Nguyen T, Côté S, O’Donnell K, Giesbrecht G, Letourneau N, Chan S, Meaney M. Perinatal Trajectories of Maternal Depressive Symptoms in Prospective, Community-Based Cohorts Across 3 Continents. JAMA Network Open 2023, 6: e2339942. PMID: 37883082, PMCID: PMC10603499, DOI: 10.1001/jamanetworkopen.2023.39942.Peer-Reviewed Original ResearchConceptsSelf-reported depressive symptomsMaternal depressive symptomsDepressive symptomsPerinatal periodPostnatal periodEdinburgh Postnatal Depression ScalePostnatal Depression ScaleEpidemiological Studies DepressionHealth policy guidelinesPublic health initiativesGroups of mothersCohort studyObservational cohortProspective cohortPregnancy influencesReferral guidelinesMultiple time pointsDepression ScaleMAIN OUTCOMEPregnancyPostnatal onsetStudies DepressionHealth initiativesTimely interventionCohortSystemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19
Gulati S, Hsu C, Shah S, Shah P, Zon R, Alsamarai S, Awosika J, El-Bakouny Z, Bashir B, Beeghly A, Berg S, de-la-Rosa-Martinez D, Doroshow D, Egan P, Fein J, Flora D, Friese C, Fromowitz A, Griffiths E, Hwang C, Jani C, Joshi M, Khan H, Klein E, Heater N, Koshkin V, Kwon D, Labaki C, Latif T, McKay R, Nagaraj G, Nakasone E, Nonato T, Polimera H, Puc M, Razavi P, Ruiz-Garcia E, Saliby R, Shastri A, Singh S, Tagalakis V, Vilar-Compte D, Weissmann L, Wilkins C, Wise-Draper T, Wotman M, Yoon J, Mishra S, Grivas P, Shyr Y, Warner J, Connors J, Shah D, Rosovsky R, Gandhi R, Gartrell B, Goel S, Halmos B, Makower D, O' Sullivan D, Ohri N, Sica R, Verma A, Butt O, Fiala M, Henderson J, Monahan R, Stockerl-Goldstein K, Zhou A, Bitran J, Hallmeyer S, Mundt D, Pandravada S, Papaioannou P, Patel M, Streckfuss M, Tadesse E, Thompson M, Lammers P, Loree J, Yu I, Bindal P, Lam B, Peters M, Piper-Vallillo A, Arvanitis P, Egan P, Farmakiotis D, Olszewski A, Vieira K, Angevine A, Bar M, Del Prete S, Fiebach M, Gulati A, Hatton E, Houston K, Rose S, Steve Lo K, Stratton J, Weinstein P, Garcia J, Routy B, Hoyo-Ulloa I, Gupta S, Nizam A, Pennell N, Sharifi N, Hoppenot C, Li A, Bitterman D, Choueiri T, Connors J, Demetri G, El Zarif T, Florez N, Freeman D, Giordano A, Morgans A, Nohria A, Tolaney S, Van Allen E, Xu W, Halabi S, Zhang T, Dzimitrowicz H, Leighton J, Graber J, Hawley J, Loggers E, Lyman G, Lynch R, Portuguese A, Schweizer M, Su C, Tachiki L, Vinayak S, Wagner M, Yeh A, Dansoa Y, Gatson N, Makary M, Manikowski J, Vadakara J, Yossef K, Beckerman J, Goyal S, Messing I, Provenzano D, Rao Y, Rosenstein L, Steffes D, Clement J, Cosin J, Daher A, Dailey M, Elias R, Eton O, Hosmer W, Hsu E, Jayaraj A, Mather J, Menendez A, Nadkarni R, Serrano O, Yu P, Gadgeel S, Tejwani S, Accordino M, Bhutani D, Bodin B, Hershman D, Ingham M, Khan S, Masson C, Schwartz G, Alexander M, Matar S, Reuben D, Bernicker E, Deeken J, Jeffords K, Shafer D, Cárdenas-Delgado A, Cuervo Campos R, De-la-Rosa-Martinez D, Ramirez A, Valdez-Reyes N, Gill D, Lewis M, Low C, Rhodes T, Jones M, Mansoor A, Mashru S, Werner M, Cohen A, Hayes-Lattin B, McWeeney S, Nemecek E, Williamson S, Lewis G, Smith S, Akhtari M, Castillo D, Cortez K, Park K, Reeves M, Berg S, O'Connor T, Altman J, Gurley M, Mulcahy M, Wehbe F, Durbin E, Kulkarni A, Nelson H, Ramesh V, Sachs Z, Wilson G, Bardia A, Boland G, Gainor J, Peppercorn J, Reynolds K, Zubiri L, Campian J, Smith K, Bekaii-Saab T, Desai A, Halfdanarson T, Joyner M, Riaz I, Senefeld J, Williams C, Bonnen M, Mahadevan D, Ramirez A, Salazar M, Wang C, Mesa R, Bouganim N, Elkrief A, Moria F, Panasci J, Papenburg J, Vinh D, Nanchal R, Singh H, Bahadur N, Bao T, Nambiar P, O’Cearbhaill R, Papadopoulos E, Philip J, Riely G, Robson M, Rosenberg J, Schoenfeld A, Tamimi R, Cerrone K, Dill J, Faller B, Ajmera A, Brouha S, Choi S, Hsiao A, Reid E, Bhatt P, Mariano M, Thomson C, Glace M, Knoble J, Rink C, Zacks R, Blau S, Brown C, Namburi S, Pomerantz L, Rovito M, Advani P, Cronin T, Fleissner B, Goel S, Gopalakrishnan D, Hernandez-Ilizaliturri F, Jain P, Kariapper A, Levine E, Moffitt M, O'Connor T, Puzanov I, Smith L, Wicher C, Zsiros E, Jabbour S, Misdary C, Shah M, Batist G, Cook E, Esfahani K, Ferrario C, Lau S, Ma K, Miller W, Rudski L, Santos Dutra M, Wilchesky M, Mahmood S, McNair C, Mico V, Rivera A, Dixon B, Heilman H, Logan B, Mandapakala C, Cabebe E, Glover M, Jha A, Khaki A, Nagpal S, Schapira L, Shah S, Wu J, Subbiah S, Whaley D, Lopes G, de Cardenas K, Russell K, Stith B, Taylor S, Klamerus J, Revankar S, Addison D, Chen J, Gatti-Mays M, Jhawar S, Palmer J, Pillainayagam C, Stover D, Wall S, Williams N, Abbasi S, Annis S, Greenland S, Jones R, Kasi A, Rock C, Wulff-Burchfield E, Smits M, Weiss M, Chism D, Owenby S, Ang C, Galsky M, Metzger M, Berenberg J, Uyehara C, Fazio A, Huber K, Lashley L, Sueyoshi M, Patel K, Riess J, Borno H, Small E, Zhang S, Andermann T, Jensen C, Rubinstein S, Wood W, Ahmad S, Grover P, Jandarov R, Kharofa J, Li N, Marcum M, Sohal D, Zamulko O, Abidi M, Balmaceda N, Bowles D, Geiger C, Markham M, Russ A, Saker H, Acoba J, Choi H, Rho Y, Feldman L, Gantt G, Hoskins K, Khan M, Liu L, Nguyen R, Pasquinelli M, Schwartz C, Venepalli N, Vikas P, Zakharia Y, Boldt A, Fecher L, Su C, Bijjula R, Mavromatis B, Seletyn M, Wood B, Zaman Q, Kaklamani V, Brown A, Charles L, Cheng A, Crispens M, Croessmann S, Davis E, Ding T, Duda S, Enriquez K, French B, Gillaspie E, Hausrath D, Hennessy C, Johnson D, Lewis J, Li X, Prescott L, Reid S, Saif S, Shyr Y, Slosky D, Solorzano C, Sun T, Wang L, Yang Y, Aboulafia D, Carducci T, Goldsmith K, Van Loon S, Topaloglu U, Moore J, Cabalona W, Shisler E, Barrow McCollough B, Peddi P, Rosen L, Bilen M, Castellano C, Ravindranathan D, Hafez N, Herbst R, LoRusso P, Lustberg M, Masters T, Stratton C, Painter C, Peters S. Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19. JAMA Oncology 2023, 9: 1390-1400. PMID: 37589970, PMCID: PMC10436185, DOI: 10.1001/jamaoncol.2023.2934.Peer-Reviewed Original ResearchConceptsThromboembolic eventsVenous thromboembolismArterial thromboembolismRelative riskTreatment of interestCohort studyMAIN OUTCOMECOVID-19Laboratory-confirmed SARS-CoV-2 infectionHigher intensive care unit admissionMultivariable log-binomial regression analysisRegistry-based retrospective cohort studyHistory of VTEIncidence of VTEIntensive care unit admissionLog-binomial regression analysisSARS-CoV-2 infectionCare unit admissionPoor performance statusRetrospective cohort studySystemic anticancer therapyAnticancer therapyType of therapyCOVID-19 diagnosisActive cancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply